Aurora Parrotta

Aurora Parrotta

Auto-generated profile, based on publicly available information

Aurora Parrotta

Reference Center for Neuromuscular Disorders, Pasteur 2 Hospital, Nice University Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2025 in Brain and Behavior
Verified
Journal Article
Open access
APAngela Puma
Angela Puma
APAurora Parrotta
Aurora Parrotta
NANicolas Azulay
Nicolas Azulay
AEAndra Ezaru
Andra Ezaru
MCMichele Cavalli
Michele Cavalli
CRCharles Raffaelli
Charles Raffaelli
Introduction/aims: Chronic inflammatory demyelinating polyneuropathy (CIDP) and its variants are characterized by nerve enlargement (NE), particularly in the proximal segments of the median nerve (MN) and cervical roots, as assessed by ultrasound (US). NE is typically moderate and seldom exceeds double the normal size of the cross‐sectional area (CSA). Furthermore, limited knowledge exists regarding the changes in the internal structure of nerves evaluated with high‐frequency ultrasound. This study describes three cases of significant CIDP‐NE assessed with an ultra‐high‐frequency probe (UHF‐US; 33 MHz) showing how changes in US‐nerve images may guide treatment choice. Methods: Three patients diagnosed with multifocal CIDP and followed for several years in our department were studied. Clinical evaluations, electrodiagnostic studies (EDX), laboratory analyses, and UHF‐US of the nerves were performed. Results: Nerve conduction studies (NCS) revealed severe demyelinating neuropathy with conduction blocks, reduced motor conduction velocities (MCV) in all cases, and secondary axonal degeneration in two cases. Ultrasound showed NE in the roots and nerves, with altered echogenicity and modification of internal nerve structure. A second‐line treatment was successfully started in three patients. Discussion: UHF‐US allows for the evaluation of structural changes in the nerve. NE and alterations in internal structure can be considered ultrasound markers of disease severity, guiding therapeutic decisions.

2 February 2026 in Journal of Neuromuscular Diseases
Verified
Journal Article
Open access
AAAhmed Amara
Ahmed Amara
MCMichele Cavalli
Michele Cavalli
AEAndra Ezaru
Andra Ezaru
APAngela Puma
Angela Puma
JGJérémy Garcia
Jérémy Garcia
SSSabrina Sacconi
Sabrina Sacconi
Background: There is a considerable challenge in managing non-dystrophic myotonias (NDM), due to the lack of gold-standard outcome measures to assess NDM burden on activities of daily living and quality of life from the patient's perspective. Objective: In this study, we aim to develop and validate a specific NDM patient-reported outcome (PRO) questionnaire. Methods: The Active-NDM questionnaire was developed through a modified 2-round Delphi procedure integrating feedback from stakeholders and a systematic literature review, with input from 11 national clinical experts. The questionnaire was validated in a pilot study of 10 patients with NDM. Both clinical experts and patients assessed questions for pertinence/relevance and clarity. We excluded questions that were not considered pertinent/relevant, and reformulated any judged to be poorly formulated, by >80% of the experts/patients. We also excluded questions with <80% reproducibility during the pilot study. Results: Based on feedback from experts and findings of the systematic literature review, we identified 130 questions, of which 100 were unduplicated. During the Delphi process, we removed 66 questions due to lack of pertinence and/or relevance. In the pilot study, patients with NDM evaluated the resulting 34-questions for pertinence, clarity, and reproducibility. Subsequently we removed 9 questions that did not achieve the required level of reproducibility. Conclusion: We developed the Active-NDM questionnaire, composed by 25 questions, figuring as a new NDM-specific measure to determine the impact of the disease on patients’ activities of daily living and quality of life. Active-NDM could be a valuable tool in the management of patients with NDM. These findings should be interpreted as preliminary. Larger-scale validation studies are warranted to confirm the tool's psychometric properties and generalizability. ClinicalTrials.gov identifier: NCT06136416

9 November 2026 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
NGNicolae Grecu
Nicolae Grecu
APAngela Puma
Angela Puma
APAurora Parrotta
Aurora Parrotta
MCMichele Cavalli
Michele Cavalli
AEAndra Ezaru
Andra Ezaru
CTCristina Tiu
Cristina Tiu